Stephane Bancel Sells 11,046 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNA) CEO Stephane Bancel sold 11,046 shares of the firm’s stock in a transaction on Monday, April 5th. The stock was sold at an average price of $129.77, for a total transaction of $1,433,439.42. Following the transaction, the chief executive officer now directly owns 6,378,868 shares of the company’s stock, valued at $827,785,700.36. The sale was disclosed in a document filed with the SEC, which is available through this link.

Stephane Bancel also recently made the following trade(s):

  • On Wednesday, March 31st, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $121.10, for a total value of $1,089,900.00.
  • On Friday, March 26th, Stephane Bancel sold 11,046 shares of Moderna stock. The stock was sold at an average price of $132.76, for a total transaction of $1,466,466.96.
  • On Wednesday, March 24th, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $137.07, for a total transaction of $1,233,630.00.
  • On Thursday, March 18th, Stephane Bancel sold 19,000 shares of Moderna stock. The stock was sold at an average price of $146.94, for a total transaction of $2,791,860.00.
  • On Friday, March 12th, Stephane Bancel sold 11,046 shares of Moderna stock. The shares were sold at an average price of $135.73, for a total value of $1,499,273.58.
  • On Wednesday, March 10th, Stephane Bancel sold 9,000 shares of Moderna stock. The stock was sold at an average price of $133.24, for a total value of $1,199,160.00.
  • On Friday, March 5th, Stephane Bancel sold 11,046 shares of Moderna stock. The stock was sold at an average price of $128.18, for a total value of $1,415,876.28.
  • On Friday, February 26th, Stephane Bancel sold 11,046 shares of Moderna stock. The shares were sold at an average price of $154.70, for a total value of $1,708,816.20.
  • On Wednesday, February 17th, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $174.28, for a total transaction of $1,568,520.00.
  • On Friday, February 12th, Stephane Bancel sold 11,046 shares of Moderna stock. The stock was sold at an average price of $181.98, for a total transaction of $2,010,151.08.

Moderna stock opened at $131.47 on Thursday. The firm has a market cap of $52.66 billion, a price-to-earnings ratio of -81.15, a price-to-earnings-growth ratio of 0.53 and a beta of 1.73. Moderna, Inc. has a 1 year low of $31.32 and a 1 year high of $189.26. The firm’s 50 day moving average price is $142.99 and its two-hundred day moving average price is $120.18. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.43 and a current ratio of 2.43.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.44). Moderna had a negative return on equity of 28.11% and a negative net margin of 242.73%. The company had revenue of $570.80 million during the quarter, compared to analyst estimates of $279.41 million. During the same quarter in the previous year, the firm earned ($0.37) earnings per share. The business’s revenue was up 3948.2% compared to the same quarter last year. As a group, equities analysts predict that Moderna, Inc. will post -1.5 EPS for the current fiscal year.

MRNA has been the subject of a number of analyst reports. Wells Fargo & Company boosted their target price on shares of Moderna from $129.00 to $145.00 and gave the company an “equal weight” rating in a research note on Monday, February 1st. Oppenheimer increased their price objective on Moderna from $178.00 to $206.00 and gave the stock an “outperform” rating in a report on Monday, February 1st. Chardan Capital lifted their target price on Moderna from $107.00 to $182.00 and gave the company a “buy” rating in a research note on Monday, March 8th. Barclays increased their price target on Moderna from $169.00 to $178.00 in a research note on Friday, February 26th. Finally, Piper Sandler restated an “overweight” rating and set a $208.00 price objective on shares of Moderna in a research note on Monday, March 22nd. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and nine have assigned a buy rating to the company. Moderna presently has an average rating of “Hold” and an average price target of $150.56.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Gerber Kawasaki Wealth & Investment Management boosted its holdings in shares of Moderna by 0.9% in the fourth quarter. Gerber Kawasaki Wealth & Investment Management now owns 7,420 shares of the company’s stock worth $775,000 after buying an additional 65 shares during the period. Simon Quick Advisors LLC grew its position in Moderna by 4.7% during the 4th quarter. Simon Quick Advisors LLC now owns 1,570 shares of the company’s stock worth $164,000 after purchasing an additional 70 shares in the last quarter. Carl P. Sherr & Co. LLC raised its stake in Moderna by 1.4% during the 4th quarter. Carl P. Sherr & Co. LLC now owns 5,227 shares of the company’s stock valued at $546,000 after purchasing an additional 74 shares during the period. Harvest Fund Management Co. Ltd lifted its holdings in shares of Moderna by 3.2% in the fourth quarter. Harvest Fund Management Co. Ltd now owns 2,876 shares of the company’s stock valued at $300,000 after purchasing an additional 90 shares in the last quarter. Finally, Patten & Patten Inc. TN boosted its position in shares of Moderna by 1.3% in the fourth quarter. Patten & Patten Inc. TN now owns 8,370 shares of the company’s stock worth $874,000 after buying an additional 110 shares during the period. Hedge funds and other institutional investors own 51.21% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics.

Recommended Story: Call Option

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.